Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Michael Nebozhyn
Merck & Co., Inc.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
97
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Identification of Biomarkers that May Extend the Utility of Anti EGFR Therapies to Subpopulations of Right-Sided and Mutant RAS Metastatic Colorectal Cancer
Number of pages: 24
Posted: 31 Dec 2024
Ramya Thota
,
Nishant Gandhi
,
Mingli Yang
,
Michael Schell
,
Lance Pflieger
,
Andrey Loboda
, Michael Nebozhyn,
Ninad Kulkarni
,
Emily Palombo
,
Andrew Elliott
,
Joanne Xiu
,
George W. Sledge
,
Moh'd M. Khushman
,
Emil Lou
,
SANJAY GOEL
,
Warren Jack Pledger
and
Timothy Yeatman
Intermountain Healthcare, Caris Life Sciences, University of South Florida, Moffitt Cancer Center & Research Institute, Buck Institute for Research on Aging, Merck & Co., Inc., Merck & Co., Inc., Caris Life Sciences, Caris Life Sciences, Caris Life Sciences, Caris Life Sciences, Caris Life Sciences, Washington University in St. Louis - School of Medicine, University of Minnesota - Minneapolis, Rutgers University, New Brunswick - Rutgers Cancer Institute of New Jersey, University of South Florida - Tampa General Hospital and University of South Florida
Downloads
97
(704,534)
View PDF
Download
Abstract:
Colorectal cancer, EGFR inhibitors, Right sided colon, Left sided colon, KRAS mutation
Feedback
